Clarient's Mammostrat to Enter Breast Cancer Recurrence Market as LDT by Fourth Quarter

Eyeing a commercial launch for Mammostrat in the fourth quarter of this year, Clarient highlighted publication of data further validating the test as “an aid for risk stratifying early stage hormone receptor-treated breast cancer patients."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.